Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kymera Therapeutics, Inc.KYMR · Entity 3545 | Chief Scientific Officer | August 27, 2021 | August 27, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kymera Therapeutics, Inc.
Report date August 27, 2021 · Filed August 27, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2021-08-27 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-08-27 · Exercise / conversion · Acquired 33,779 · Balance 33,779 Row 2 · 2021-08-27 · Sale · Disposed 33,779 · Balance 0 F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $59.99 to $60.69. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.00 · Expires 2030-08-19 | Direct | 263,340 |
Reported balance
After 2021-08-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-08-27 · Exercise / conversion · Disposed 33,779 · Balance 263,340 F3: Twenty-five percent (25%) of the shares subject to this option vested and became exercisable on August 17, 2021, and the remainder of the shares shall vest in equal monthly installments for a period of thirty-six (36) months thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $59.99 to $60.69. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3: Twenty-five percent (25%) of the shares subject to this option vested and became exercisable on August 17, 2021, and the remainder of the shares shall vest in equal monthly installments for a period of thirty-six (36) months thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 27, 2021 Filed Aug 27, 2021 16:55 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 33,779 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001209191-21-053642 · doc4.xml · derivative · entry 3 Chesworth Richard · CIK 0001821188 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,340 Underlying: Common Stock · 33,779 shares Expires 2030-08-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option vested and became exercisable on August 17, 2021, and the remainder of the shares shall vest in equal monthly installments for a period of thirty-six (36) months thereafter. Read SEC document |
| August 27, 2021 Filed Aug 27, 2021 16:55 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 33,779 | $60.12 | $2,030,864.42 |
DisclosureSEC source: 0001209191-21-053642 · doc4.xml · nonDerivative · entry 2 Chesworth Richard · CIK 0001821188 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $59.99 to $60.69. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 27, 2021 Filed Aug 27, 2021 16:55 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 33,779 | $20.00 | $675,580.00 |
DisclosureSEC source: 0001209191-21-053642 · doc4.xml · nonDerivative · entry 1 Chesworth Richard · CIK 0001821188 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,779 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 16:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 54,000 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0000899243-21-033638 · doc4.xml · derivative · entry 6 Chesworth Richard · CIK 0001821188 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 297,119 Underlying: Common Stock · 54,000 shares Expires 2030-08-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option vested and became exercisable on August 17, 2021, and the remainder of the shares shall vest in equal monthly installments for a period of thirty-six (36) months thereafter. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 16:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 288 | $52.09 | $15,001.98 |
DisclosureSEC source: 0000899243-21-033638 · doc4.xml · nonDerivative · entry 5 Chesworth Richard · CIK 0001821188 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $52.06 to $52.16. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 16:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 2,928 | $51.68 | $151,324.60 |
DisclosureSEC source: 0000899243-21-033638 · doc4.xml · nonDerivative · entry 4 Chesworth Richard · CIK 0001821188 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $51.05 to $52.00. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 16:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 41,975 | $50.37 | $2,114,242.97 |
DisclosureSEC source: 0000899243-21-033638 · doc4.xml · nonDerivative · entry 3 Chesworth Richard · CIK 0001821188 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,216 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.04 to $51.02. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 16:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 8,809 | $49.90 | $439,612.26 |
DisclosureSEC source: 0000899243-21-033638 · doc4.xml · nonDerivative · entry 2 Chesworth Richard · CIK 0001821188 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,191 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $49.04 to $50.03. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 16:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 54,000 | $20.00 | $1,080,000.00 |
DisclosureSEC source: 0000899243-21-033638 · doc4.xml · nonDerivative · entry 1 Chesworth Richard · CIK 0001821188 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 16:52 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $48.46 | $0.00 |
DisclosureSEC source: 0000899243-21-009410 · doc4.xml · derivative · entry 1 Chesworth Richard · CIK 0001821188 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2031-02-28 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in thirty-six (36) equal monthly installments over three (3) years following the Grant Date, with the first installment vesting on April 1, 2021. Read SEC document |
| August 20, 2020 Filed Aug 21, 2020 18:28 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantStock Option (Right to Buy) · Derivative | 351,119 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0000899243-20-023241 · doc4.xml · derivative · entry 1 Chesworth Richard · CIK 0001821188 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 351,119 Underlying: Common Stock · 351,119 shares Expires 2030-08-19 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option shall vest on August 17, 2021, and the remainder of the shares shall vest in equal monthly installments for a period of thirty-six (36) months thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.